Sage Therapeutics
Presença
Sage Therapeutics é uma das ...
Sage Therapeutics é uma empresa listada sob o símbolo SAGE (US).
Executivos
Veja o organograma con seus 22 executivos principais
Biografias mais buscadas da Sage Therapeutics
- Barry Greene, Director and Chief Executive Officer
- Geno Germano, Chairman of the Board
- Steven Paul, Director
Recentes movimentos de executivos em Sage Therapeutics
- Kevin Starr, Chairman of the Board, se aposentou (Notícia publicada em 8 de janeiro de 2024).
- Geno Germano antes Director, foi promovido a Chairman of the Board (Notícia publicada em 8 de janeiro de 2024).
Criar um alerta
para seguir os movimentos de executivos da Sage Therapeutics.
Farmacêutica
Sage Therapeutics possui 1.861 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Sage Therapeutics
- Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress | Sage Therapeutics, Inc.
- Sage Therapeutics to Present at Upcoming August Investor Conferences | Sage Therapeutics, Inc.
- Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 | Sage Therapeutics, Inc.
- Sage Therapeutics to Present at Upcoming June Investor Conferences | Sage Therapeutics, Inc.
- Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints | Sage Therapeutics, Inc.
- Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress | Sage Therapeutics, Inc.
- Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Sage Therapeutics, Inc.
- Sage Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020 | Sage Therapeutics, Inc.
- Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD | Sage Therapeutics, Inc.
- Sage Therapeutics Appoints Barry Greene to Board of Directors | Sage Therapeutics, Inc.
- View more press releases Close
Redes sociais sobre Sage Therapeutics
- Sage Therapeutics na Wikipedia, Google News e Yahoo Finance
- Sage Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Barry Greene 
Ligue para a Sage Therapeutics em +1 617...
